Literature DB >> 11931767

Formation of the androgen receptor transcription complex.

Yongfeng Shang1, Molly Myers, Myles Brown.   

Abstract

Androgen receptor (AR) is required for sexual differentiation and is implicated in the development of prostate cancer. Here we describe distinct functions for cofactor proteins and gene regulatory elements in the assembly of AR-mediated transcription complexes. The formation of an activation complex involves AR, coactivators, and RNA polymerase II recruitment to both the enhancer and promoter, whereas the formation of a repression complex involves factors bound only at the promoter and not the enhancer. These results suggest a model for the functional coordination between the promoter and enhancer in which communication between these elements is established through shared coactivators in the AR transcription complex.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11931767     DOI: 10.1016/s1097-2765(02)00471-9

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  243 in total

1.  The cochaperone Bag-1L enhances androgen receptor action via interaction with the NH2-terminal region of the receptor.

Authors:  Liubov Shatkina; Sigrun Mink; Hermann Rogatsch; Helmut Klocker; Gernot Langer; Andrea Nestl; Andrew C B Cato
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

2.  RORalpha coordinates reciprocal signaling in cerebellar development through sonic hedgehog and calcium-dependent pathways.

Authors:  David A Gold; Sung Hee Baek; Nicholas J Schork; David W Rose; DeLaine D Larsen; Benjamin D Sachs; Michael G Rosenfeld; Bruce A Hamilton
Journal:  Neuron       Date:  2003-12-18       Impact factor: 17.173

3.  A human globin enhancer causes both discrete and widespread alterations in chromatin structure.

Authors:  AeRi Kim; Ann Dean
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

4.  Substrate phosphorylation and feedback regulation in JFK-promoted p53 destabilization.

Authors:  Luyang Sun; Lei Shi; Feng Wang; Peiwei Huangyang; Wenzhe Si; Jie Yang; Zhi Yao; Yongfeng Shang
Journal:  J Biol Chem       Date:  2010-12-02       Impact factor: 5.157

5.  ERalpha and ERbeta expression and transcriptional activity are differentially regulated by HDAC inhibitors.

Authors:  V Duong; A Licznar; R Margueron; N Boulle; M Busson; M Lacroix; B S Katzenellenbogen; V Cavaillès; G Lazennec
Journal:  Oncogene       Date:  2006-03-16       Impact factor: 9.867

6.  Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer.

Authors:  Derek S Welsbie; Jin Xu; Yu Chen; Laetitia Borsu; Howard I Scher; Neal Rosen; Charles L Sawyers
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

7.  BAF57 governs androgen receptor action and androgen-dependent proliferation through SWI/SNF.

Authors:  Kevin A Link; Craig J Burd; Erin Williams; Thomas Marshall; Gary Rosson; Erin Henry; Bernard Weissman; Karen E Knudsen
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

8.  FoxO1 mediates PTEN suppression of androgen receptor N- and C-terminal interactions and coactivator recruitment.

Authors:  Qiuping Ma; Wei Fu; Pengfei Li; Santo V Nicosia; Guido Jenster; Xiaohong Zhang; Wenlong Bai
Journal:  Mol Endocrinol       Date:  2008-12-12

9.  Fhl2 deficiency results in osteopenia due to decreased activity of osteoblasts.

Authors:  Thomas Günther; Cecilia Poli; Judith M Müller; Philip Catala-Lehnen; Thorsten Schinke; Na Yin; Sandra Vomstein; Michael Amling; Roland Schüle
Journal:  EMBO J       Date:  2005-08-04       Impact factor: 11.598

10.  2,2-bis(4-chlorophenyl)-1,1-dichloroethylene stimulates androgen independence in prostate cancer cells through combinatorial activation of mutant androgen receptor and mitogen-activated protein kinase pathways.

Authors:  Supriya Shah; Janet K Hess-Wilson; Siobhan Webb; Hannah Daly; Sonia Godoy-Tundidor; Jae Kim; Joanne Boldison; Yehia Daaka; Karen E Knudsen
Journal:  Mol Cancer Res       Date:  2008-09       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.